Mar 4 |
Plus Therapeutics Q4 2023 Earnings Preview
|
Dec 18 |
Plus sees an additional $6.9M in grant revenue in 2024
|
Dec 18 |
Plus Updates Financial and Cash Guidance for 2024
|
Nov 29 |
Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe
|
Nov 20 |
Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
|
Nov 15 |
Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023
|
Nov 13 |
Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals?
|
Nov 9 |
Insiders Buying Plus Therapeutics And 2 Other Stocks Under $2
|
Nov 3 |
Plus Therapeutics climbs on FDA orphan drug tag for radiotherapy
|
Nov 3 |
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases
|